- Home
- BYFC vs NRXP Comparison
BYFC vs NRXP Comparison
Compare BYFC & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BYFC | NRXP |
|---|---|---|
| Founded | 1946 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.7M | 54.2M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | BYFC | NRXP |
|---|---|---|
| Price | $7.86 | $2.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $38.00 |
| AVG Volume (30 Days) | 2.3K | ★ 797.6K |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $184,000.00 | N/A |
| Revenue This Year | N/A | $2,547.84 |
| Revenue Next Year | N/A | $1,591.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.71 | N/A |
| 52 Week Low | $5.51 | $1.65 |
| 52 Week High | $8.85 | $3.84 |
Technical Indicators
Market Signals| Indicator | BYFC | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 53.44 | 67.63 |
| Support Level | $7.69 | $2.28 |
| Resistance Level | $7.93 | $2.79 |
| Average True Range (ATR) | 0.11 | 0.14 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 91.78 | 82.73 |
Price Performance
Historical ComparisonAbout BYFC Broadway Financial Corporation
Broadway Financial Corp is active in the financial services domain. It is a savings and loan holding company in the United States. The Bank's business consists of deposits from the general public and using such deposits, together with borrowings and other funds, to make mortgage loans secured by residential properties and commercial real estate. Its deposits consist of passbook savings accounts, checking accounts, and negotiable order of withdrawal accounts, money market accounts and fixed-term certificates of deposit. The revenue is derived from interest income on loans and investments.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.